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Abstract 
Background: No conclusive evidence has been obtained yet on the significance of the effects of dipeptidyl pepti-
dase-4 (DPP-4 inhibitor) treatment on the arterial stiffness in clinical settings. In addition, the effects of good glycemic 
control on the arterial stiffness have also not been clarified yet. As a sub-analysis of the PROLOGUE study, we exam-
ined the effect of a DPP-4 inhibitor (sitagliptin) on the 2-year progression of the arterial stiffness and also to determine 
the effect of good glycemic control on the rate of progression of the arterial stiffness.
Methods: In the PROLOGUE study, the study participants were either allocated to add-on sitagliptin treatment or to 
continued treatment with conventional anti-diabetic agents. Among the 463 participants of the PROLOGUE study, we 
succeeded in measuring the brachial-ankle pulse wave velocity (baPWV) at least two times during the 2-year study 
period in 96 subjects.
Results: The changes in the baPWV during the study period were similar between the both groups (i.e., with/with-
out staglipitin), overall. On the other hand, when the study subjects were divided into two groups according to the 
glycemic control status during the study period {good glycemic control group (GC) = hemoglobin (Hb)A1c <7.0 at 
both 12 and 24 months after the treatment randomization; poor glycemic control group (PC) = HbA1c ≥7.0 at either 
12 months, 24 months, or both}, the 2-year increase of the baPWV was marginally significantly larger in the PC group 
(144 ± 235 cm/s) as compared to that the GC group (−10 ± 282 cm/s) (p = 0.036).
Conclusion: While the present study could not confirm the beneficial effect of sitagliptin per se on the arterial stiff-
ness, the results suggested that good glycemic control appears to be beneficial for delaying the annual progression of 
the arterial stiffness.
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Background
Arterial stiffness, as assessed by the pulse wave veloc-
ity (PWV), is known as an independent risk factor for 
cardiovascular disease [1, 2], and PWV is reported as 
a useful marker to predict the progression of diabetic 
nephropathy and occurrence of future cardiovascu-
lar events in patients with diabetes [3–5]. Some studies 
have reported that the treatment of diabetes is associated 
with a reduction of the arterial stiffness [6–9]. Recently, 
new orally administered dipeptidyl peptidase 4 (DPP-4) 
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inhibitors have become available for the treatment of 
diabetes [10]. Several experimental studies have dem-
onstrated the beneficial effects of DPP-4 inhibition on 
diabetic vascular damage [11], however, no conclusive 
evidence has been obtained yet on the significance of the 
effects of DPP-4 inhibitor treatment on the arterial stiff-
ness in clinical settings. In addition, while DPP-4 inhibi-
tors are thought to be able to provide better glycemic 
control without increasing the risk of hypoglycemia [10], 
the effects of good glycemic control on the arterial stiff-
ness have also not been clarified yet.
The PROLOGUE study was a prospective multicenter 
study carried out to examine the effect of add-on DPP4 
inhibitor therapy on the progression of the carotid 
intima-media thickness (IMT) over a 2-year follow-up 
period [12, 13]. In this study, the PWV was also measured 
in some of the study participants. The arterial stiffness is 
known to increase annually in subjects [14, 15]. There-
fore, we carried out the present study as a sub-analysis of 
the PROLOGUE study to examine the following
1. The effect of DPP4 inhibitor therapy on the rate of 
progression of the arterial stiffness, and
2. The effect of good glycemic control on the rate of 
progression of the arterial stiffness.
Methods
Study design and patients
The rationale and design of the PROLOGUE study (Uni-
versity hospital Medical Information Network Center: 
ID 000004490) have been described previously [12, 13]. 
In brief, it was a multicenter, prospective, randomized, 
open-label, blinded-endpoint trial carried out with the 
participation of 48 Japanese institutions. The trial was 
approved by the ethics committee of each center and 
all the patients provided written informed consent. We 
enrolled 463 patients with T2DM between June 2011 and 
September 2012. The inclusion criteria and exclusion cri-
teria are described elsewhere [12, 13]. The patients were 
randomized to either add-on sitagliptin treatment (sitag-
liptin group) or to continued treatment with conventional 
anti-diabetic agents (conventional antidiabetic treatment 
group). In both groups, the target glycemic control level 
was “maintenance of the HbA1c value at <6.2% or of the 
fasting blood glucose at <110 mg/dl throughout the study 
period”. The treatment randomization was conducted 
based on the age, gender, use of statins, pre-treatment 
diabetes type (non-pharmacological or pharmacologi-
cal treatment), HbA1c (<7 or ≥7%), office systolic blood 
pressure (<135 or  ≥135  mmHg) and maximum IMT 
(<1.0 or ≥1.0 mm) [12, 13]. All the patients were followed 
up annually for 2 years until September 2014.
Measurement of the brachial‑ankle pulse wave velocity 
(baPWV)
In the PROLOGUE study, the primary endpoint was the 
change in the mean common carotid artery (CCA)-IMT 
at 24  months after treatment randomization. Carotid 
ultrasound examinations were performed 1 month prior 
to, or at the time of inclusion of the patient in the study, 
and then at 12 and 24  months after the treatment ran-
domization. In some of the participating centers, the 
baPWV was also measured as an ad hoc examination 
1 month prior to, or at the time of inclusion of the subject 
in the study, and then at 12 and 24 months after the treat-
ment randomization (Supplementary text 1 in ref. 13).
The baPWV was measured using a volume-plethysmo-
graphic apparatus (Form/ABI; Colin Co. Ltd., Komaki, 
Japan), as previously described [15, 16]. In brief, occlusion 
cuffs, connected to both the plethysmographic and oscil-
lometric sensors, were attached to both the upper arms 
and ankles while the subjects lay in the supine position. 
The brachial and posterior-tibial arterial pressures were 
measured using the oscillometric sensors. The measure-
ments were conducted after the subjects had rested for 
at least 5  min in the supine position, in a temperature-
controlled room (24–26  °C) designated exclusively for 
this purpose. The distance between the sampling points 
for the brachial-ankle PWV was calculated automati-
cally according to the height of the subject. The path 
length from the suprasternal notch to the brachium (Lb) 
was obtained from superficial measurements and was 
expressed using the equation, Lb = 0.2195 × height of the 
patient (in centimeters)—2.0734. The path length from 
the suprasternal notch to the ankle (La) was obtained 
from superficial measurements and was expressed using 
the equation, La  =  (0.8129  ×  height of the patient (in 
centimeters)  +  12.328). Finally, the following equation 
was used to calculate the brachial-ankle PWV: brachial-
ankle PWV = (La − Lb)/ΔTba. (ΔTba is the time interval 
between the wavefront of the brachial waveform and that 
of the ankle waveform).
Laboratory examinations
Blood samples were taken under the fasting condition 
from the subjects. The serum malondialdehyde low den-
sity-lipoprotein cholesterol (MDA-LDL) concentrations 
were measured by enzyme-linked immunosorbent assay 
(SRL Co. Tokyo, Japan). The serum 1,5 anhydroglucitol 
(1,5 AG) concentrations were measured enzymatically 
(SRL Co. Tokyo, Japan). The serum C-reactive protein 
(CRP) concentrations were determined by the latex-
aggregation method (SRL Co. Tokyo, Japan), which is a 
high-sensitivity assay method with a detection threshold 
of <0.1 mg/L.
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Statistics
Data were expressed as mean ±  SD. The delta changes 
of the variables during the study period were calculated 
as the values obtained at 12 or 24 months after the treat-
ment randomization minus the values obtained at the 
baseline. The differences in the measured values between 
the baseline and at 12 or 24 months after the treatment 
randomization were assessed by the paired t test. McNe-
mar’s non-parametric test was applied for assessment of 
the differences in the categorical variables between the 
baseline and at 12 or 24 months after the treatment ran-
domization. The differences between the groups were 
assessed by the Mann–Whitney U-test or Chi square 
test. General linear model analysis with post hoc com-
parison was also applied for assessing the differences in 
the variables between the groups after adjustments for 
covariates. The associations among the variables were 
assessed by univariate linear regression analysis.
All the analyses were conducted using the SPSS soft-
ware for Windows, version 19.0  J (IBM/SPSS Inc., Chi-
cago, IL); p < 0.05 was considered to indicate statistically 
significant difference.
Results
Among the 463 subjects who participated in the PRO-
LOGUE study, the baPWV was measured at the base-
line in 134 subjects, and again at the end of 1 year and/
or 2  years after the treatment randomization in 107 
subjects. Among these subjects, the data of 11 subjects 
with atrial fibrillation and/or ABI  <  0.90 were excluded 
from the study (The accuracy of baPWV is attenuated 
in these conditions), and finally, the data of 96 subjects 
were analyzed. In the overall subject population (n = 96), 
while the HbA1c decreased from 6.9  ±  0.6% (base-
line) to 6.7 ±  0.6% (at 24  months after treatment rand-
omization), no significant change of the baPWV (from 
1710 ± 318 to 1725 ± 367 cm/s) or blood pressure (from 
130  ±  14/72  ±  11 to 131  ±  16/73  ±  10  mmHg) was 
observed during the study period.
Table  1 shows the clinical characteristics of the study 
subjects in the sitagliptin and conventional anti-diabetic 
treatment groups, and no significant differences in the 
characteristics were observed between the two groups. In 
both groups, significant decrease of the HbA1c level was 
observed, and a tendency towards a lower HbA1c value 
at 24  months after the treatment randomization in the 
sitagliptin group as compared to that in the conventional 
anti-diabetic treatment group was observed (p = 0.076) 
(Fig. 1). On the other hand, no significant change of the 
baPWV was observed during the study period in either 
group.
When the study subjects were divided into two groups 
according to the glycemic control status during the 
study period {good glycemic control group  =  hemo-
globin (HbA1c)  <7.0 at both 12 and 24  months after 
the treatment randomization; poor glycemic control 
group =  HbA1c ≥7.0 at either 12, 24  months, or both, 
after the treatment randomization}, while no significant 
change of the baPWV was noted in the good glycemic 
control group, the baPWV increased significantly in the 
poor glycemic control group during the study period 
(Fig. 2). Table 2 shows the clinical characteristics of the 
subjects of the good glycemic control and poor glycemic 
Table 1 Clinical characteristics of  the study subjects 
assigned to  the add-on sitagliptin group and  continued 
therapy with conventional antidiabetic agents at baseline
n number of study subjects, BMI body mass index, SBP systolic blood pressure, 
DBP diastolic blood pressure, brPP brachial pulse pressure, HR heart rate, Current 
smoker number of current smokers, TC serum total cholesterol, HDL serum high-
density lipoprotein cholesterol, TG serum triglyceride, Crnn serum creatinine, 
eGFR creatinine-based estimated glomerular filtration rate, FBG fasting blood 
glucose, Hypertension number of subjects with hypertension, Dyslipidemia 
number of subjects with dyslipidemia, Cerebrovascular disease number of 
subjects with cerebrovascular disease, Cardiovascular disease number of subjects 
with cardiovascular disease, Insulin number of subjects treated with insulin, 
Biguanides number of subjects treated with biguanides, Sulfonylureas number 
of subjects treated with sulfonylureas, Others number of subjects treated with 






Age 70 ± 8 69 ± 9 0.501
Gender (m/f ) 29/16 33/18 0.574
BMI 25.5 ± 3.4 25.5 ± 4.4 0.956
SBP (mmHg) 131 ± 12 130 ± 16 0.643
DBP (mmHg) 74 ± 11 71 ± 12 0.256
HR (beats/min) 67 ± 12 69 ± 11 0.389
Current smoker 3 6 0.412
TC (mmol/L) 4.5 ± 0.8 4.5 ± 0.8 0.879
HDL (mmol/L) 1.3 ± 0.3 1.3 ± 0.4 0.996
TG (mmol/L) 1.5 ± 0.7 1.7 ± 1.0 0.176
Crnn (μmol/L) 76 ± 20 75 ± 21 0.805
eGFR (mL/min per 
1.73 m2)
65 ± 16 67 ± 17 0.675
FBG (mmol/L) 6.8 ± 1.6 7.3 ± 1.9 0.560
Hemoglobin A1c 
(%)
6.9 ± 0.6 7.0 ± 0.6 0.560
Hypertension 38 40 0.313








 Insulin 0 0
 Biguanides 7 10 0.403
 Sulfonylureas 10 11 0.566
 Others 21 30 0.162
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control groups. At the baseline, the subjects of the poor 
glycemic control group had a tendency toward a higher 
blood pressure as compared with those of the good gly-
cemic control group. No significant changes of the serum 
MDA-LDL, hsCRP and 1,5 AG levels were observed in 
the poor glycemic control group during the study period, 
while the serum MDA-LDL and 1,5 AG concentrations 
increased significantly from the baseline to 24  months 
after the treatment randomization in the good glycemic 
control group (Table 2).
We examined the variables that showed a significant 
relationship to the change of the baPWV from the base-
line to the end of the 24-month study period. Among 
the variables {age, gender, sitagliptin treatment (yes/
no) and the clinical characteristics (body mass index, 
systolic blood pressure, heart rate, serum levels of total 
cholesterol, high-density lipoprotein cholesterol, tri-
glycerides and HbA1c) at the baseline, at 24  months, 
and their changes from the baseline to the end of the 
24-month study period}, the magnitude of change of the 
baPWV from the baseline to the end of the 24-month 
study period was significantly correlated with the magni-
tudes of change of the systolic blood pressure (R = 0.415, 
p < 0.001) and heart rate (R = 0.287, p = 0.017) during 
the same period, and marginally significantly with the 
HbA1c level at 24 months (R = 0.217, p = 0.075). Then, 
the magnitude of change of the baPWV from the baseline 
to 24 months after the treatment randomization (n = 69) 
was significantly higher in the poor glycemic control 
group as compared to that in the good glycemic control 
group (Fig.  3). This difference remained marginally sig-
nificant even after adjustments for changes of the blood 
pressure and heart rate from the baseline to the end of 
the 24-month study period.
The subjects of the good glycemic control group 
(n  =  53) were further subdivided into two groups 
based on the glycemic control status during the study 
period {intensive glycemic control group = HbA1c <6.5 
at both 12 and 24  months after the treatment rand-
omization; non-intensive, but good glycemic control 
group  =  HbA1c  >6.5 at either 12, 24  months, or both, 
after the treatment randomization}. The change of the 































0       12M              24M 
* * 
P=0.076 
Sita  n= 45 44        30 
Cont n=51 44        39 
Sita  n= 45 44        41 
Cont n=51 50        47 
0       12M              24M 
* * 
Fig. 1 Changes of the brachial-ankle pulse wave velocity and serum 
hemoglobin A1c levels in subjects assigned to add-on sitagliptin 
treatment or continuation of therapy with conventional antidiabetic 
agents. baPWV brachial-ankle pulse wave velocity, HbA1c hemoglobin 
A1c, Sita (empty circles) subjects assigned to add-on sitagliptin treat-
ment, Cont (filled circles) subjects assigned to continued treatment 
with conventional antidiabetic agents, 0 baseline, 12 M 12 months 




















GC<7.0  n= 72        66               53 
GC>7.0  n= 24        22               16 
Fig. 2 Changes of the brachial-ankle pulse wave velocity in the study 
subjects with and without good glycemic control during the study 
period. GC < 7.0 (empty squares) subjects with good glycemic control, 
GC > 7.0 (filled squares) subjects with poor glycemic control, *p < 0.05 
vs. baseline; other abbreviations are as described in the footnote for 
Fig. 1
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randomization was similar between the intensive glyce-
mic control (n = 24; 19.5 ± 52.6) and non-intensive, but 
good glycemic control groups (n  =  29; −33.8  ±  56.3) 
(p = 0.728).
Discussion
The novel finding of the present study was that the annual 
rate of progression of arterial stiffness was significantly 
lower in the subjects with good glycemic control than in 
those with poor glycemic control.
A recent Cochrane meta-analysis reported that inten-
sive glycemic control was not associated with any sig-
nificant difference in the all-cause or cardiovascular 
mortality rates as compared to conventional glycemic 
control [17]. Therefore, further studies to evaluate the 
association of the glycemic control status with the risk of 
cardiovascular events, especially their association with 
the pathophysiological abnormalities related to cardio-
vascular risk, are needed. Increased arterial stiffness is 
thought to act as a risk factor for cardiovascular diseases 
via inducing increased cardiac afterload, impaired coro-
nary blood flow, microvascular damage, etc. [1, 2, 18]. 
Thus, it is crucial to examine the effect of the glycemic 
control status on the arterial stiffness.
Not only a previous cross-sectional study, but also a 
previous prospective observational study has reported 
that insufficient glycemic control is related to increased 
arterial stiffness [19, 20]. On the other hand, contro-
versial results have been reported about the effect of 
glycemic control on the arterial stiffness [6, 21]. In the 
overall subject population in this study, the HbA1c value 
decreased from 6.9 to 6.7%, however, this small reduction 
of the HbA1c value was not associated with any signifi-
cant reduction of the arterial stiffness. However, when 
the subjects were divided into 2 groups based on the gly-
cemic control status during the study period, while the 
baPWV increased significantly during the 2-year study 
period in the subjects with poor glycemic control, no 
significant change was found in the subjects with good 
glycemic control. Some prospective studies have demon-
strated a significant annual progression of arterial stiff-
ness in healthy subjects [14, 15]. This is mentioned in the 
3rd paragraph of the Discussion section as follows: While 
a gender difference in age-related progression of arte-
rial stiffness has been reported [22], in the present study, 
analysis by the Chi square test demonstrated no signifi-
cant difference in the gender distribution between the 
good glycemic control and poor glycemic control groups. 
In addition, the gender did not affect the change of the 
baPWV from the baseline to the end of the 24-month 
study period. Our previous prospective study demon-
strated that even mild elevation of the blood sugar levels 
(>110  mg/dl) accelerated this age-related progression of 
arterial stiffness [23]. In the present study, sustained good 
glycemic control status appeared to counteract the age-
related progression of arterial stiffness.
In diabetes mellitus, oxidative stress and/or inflam-
mation are thought to contribute to the increase in the 
arterial stiffness [5, 24]. However, in the present study, 
the serum CRP, a marker of inflammation, was similar 
between the subjects with and without good glycemic 
control. Oddly enough, the serum MDA-LDL, a marker 
of oxidative stress, was rather higher in the subjects with 
good glycemic control. Thus, in the present study, good 
glycemic control appeared to counteract age-related pro-
gression of arterial stiffness via some mechanisms other 
than anti-inflammatory and/or anti-oxidant mechanisms. 
Apart from these atherogenic factors, advanced end-
glycation products (AGEs) have also been reported to 
contribute to increasing the arterial stiffness in patients 
with diabetes via accumulating in tissues and the cross-
link collagen in arterial wall [5, 24]. In the present study, 
serum 1,5 AG levels were also higher in the subjects with 
good glycemic control than in the subjects with poor 
glycemic control. Hyperglycemia and its duration are 
thought to contribute to the production of AGEs. Thus, 
while we did not measure the markers related to AGEs in 
the present study, one of the plausible mechanisms is that 
the lower production of AGEs associated with good gly-
cemic control may contribute to delaying the progression 
of arterial stiffness.
It has not yet been conclusively determined as to which 
target level of HbA1c, i.e., HbA1c <6.5% or HbA1c <7.0%, 
might be the more appropriate target level representing 
good glycemic control [25]. In the present study, when 
the patients were further subclassified according to the 
glycemic control status into an intensive glycemic con-
trol group (HbA1c <6.5%) and a non-intensive, but good 
glycemic control group (HbA1c 6.5–7.0%), no significant 
difference of the changes of the baPWV during the study 
period was observed between the two groups. While 
intensive glycemic control is thought to be beneficial 
against inflammation, oxidative stress, and/or accumu-
lation of AGEs, transient hypoglycemia associated with 
intensive control might activate the sympathetic tone 
[5, 25]; thus, intensive glycemic control may have some 
counteractive effects on the arterial stiffness.
Some studies have reported that pioglitazone improves 
the vascular functions (i.e., endothelial function and/or 
arterial stiffness) independent of its effect on glycemia 
control [8, 9]. It is believed that these beneficial effects 
may have derived from the anti-inflammatory and/or 
anti-oxidant effects of pioglitazone. While experimen-
tal studies have reported a similar beneficial effect of 
the DPP4 inhibitors on the vascular functions [11], two 
single-center studies could not confirm the beneficial 
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effect in clinical settings [26, 27]. Furthermore, no ben-
eficial effect of sitagliptin per se on the arterial stiffness, 
independent of its effect on the glycemic control, was 
observed in the present multicenter study either. How-
ever, in one reported study by Matsubara et al., a DPP4 
inhibitor was shown to improve the endothelial function 
[28]. Improved endothelial function may affect the arte-
rial stiffness, therefore, a prospective study with a long 
follow-up duration (more than 2  years) is proposed to 
clarify whether sitagliptin may exert a beneficial effect on 
the arterial stiffness, independent of its effect on the gly-
cemic control.
While the TECOS study and EXAMINE study failed 
to confirm improvement of the cardiovascular outcomes 
by DPP-4 inhibitor treatment [29], the study period in 
both of these studies was less than 3 years. Some studies 
have already demonstrated that DPP-4 inhibitor treat-
ment yields beneficial effects on abnormalities related 
to cardiovascular disease [30, 31]. Increased arterial 
stiffness is also an independent risk factor for future 
cardiovascular events [1, 2, 4]. Thus, further studies 
with long follow-up periods are needed to examine the 
effects of DPP-4 inhibitor treatment on the cardiovas-
cular outcomes.
Study limitations
The present study had some limitations, as follows; (1) 
The present study was a sub-analysis of PROLOGUE 
study, and therefore, the CONSORT statement could 
not be compliant [32]; (2) while the baPWV reflects the 
stiffness of the middle-to-large arteries, stiffness of the 
large arteries is thought to be a cardiovascular risk fac-
tor. Thus, the beneficial effect of good glycemic control 
on the progression of large arterial stiffness needs to be 
examined using the carotid-femoral PWV [1, 4, 18]; (3) 
The present study was a sub-analysis of the PROLOGUE 
study, therefore, the number of study subjects (espe-
cially the number of subjects with poor glycemic control) 
was relatively small, and some of them could not obtain 
data completely. Confirmation of the results of the pre-
sent study in a larger number of study subjects and also 
in subjects of other ethnicities is proposed; (4) We could 
not explore the mechanisms underlying the significant 
elevation of the serum MDA-LDL concentrations in the 
subjects with good glycemic control in this study.
Table 2 Clinical characteristics of  the study subjects with  and without  good glycemic control during  the study period 
at baseline and at the end of 24 months of treatment
GC < 7.0 subjects with good glycemic control, GC > 7.0 subjects with poor glycemic control, 24 M at the end of 24 months of treatment, MDA-LDL serum concentration 
of malondialdehyde low density-lipoprotein cholesterol concentrations, CRP serum concentration of C-reactive protein, 1,5 AG serum 1,5 anhydroglucitol 
concentrations, p value comparison between the baseline and after 24 months of treatment, # p = 0.062, * p < 0.050 and ** p < 0.010 vs. subjects without good 
glycemic control, Other abbreviations are as described in the footnote for Table 1
Parameters GC < 7.0 (n = 72) GC ≥ 7.0 (n = 24)
Baseline 24 M p value Baseline 24 M p value
Age 70 ± 9 67 ± 9
Gender (m/f ) 49/23 13/11
BMI 25.3 ± 3.6 25.4 ± 3.8 ns 26.1 ± 4.9 25.8 ± 5.0 ns
SBP (mmHg) 128 ± 13# 130 ± 16 ns 136 ± 16 135 ± 17 ns
DBP (mmHg) 71 ± 10 72 ± 9* ns 75 ± 13 77 ± 9 ns
HR (beats/min) 68 ± 12 69 ± 13 ns 70 ± 11 70 ± 10 ns
Hemoglobin A1c (%) 6.7 ± 0.4** 6.4 ± 0.3** p < 0.001 7.5 ± 0.7 7.5 ± 0.7 ns
MDA-LDL (U/L) 106 ± 39 118 ± 34 P = 0.005 111 ± 52 124 ± 42 ns
CRP (ng/mL) 1104 ± 1559 1768 ± 6874 ns 658 ± 745 907 ± 1181 ns




















Fig. 3 Changes of the brachial-ankle pulse wave velocity from the 
baseline to 24 months after the treatment randomization in subject 
groups stratified by the glycemic control status. deltabaPWV baPWV 
value at 24 months after the treatment randomization minus that 
value at the baseline; other abbreviations are as described in the 
footnotes for Figs. 1 and 2
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Conclusion
While the present study could not confirm the beneficial 
effect of sitagliptin per se on the arterial stiffness, good 
glycemic control (HbA1c  <7.0) appears to be beneficial 
for delaying the annual progression of arterial stiffness. 
Increased arterial stiffness is thought to contribute to 
the occurrence of future cardiovascular events via sev-
eral mechanisms such as increase in cardiac afterload, 
impaired coronary blood flow, microvascular damage 
(i.e., pulsatile nephropathy and encephalopathy) and/
or atherogenic actions. The next logical step would be 
to clarify whether the attenuated progression of arterial 
stiffness associated with sustained good glycemic con-
trol might also be associated with a reduced risk of future 
cardiovascular events.
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